<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-14085R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0008646</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology</subject><subject>Oncology</subject><subject>Immunology/Immune Response</subject><subject>Immunology/Immunomodulation</subject><subject>Immunology/Innate Immunity</subject><subject>Oncology/Prostate Cancer</subject></subj-group></article-categories><title-group><article-title>iNKT Cells Control Mouse Spontaneous Carcinoma Independently of Tumor-Specific Cytotoxic T Cells</article-title><alt-title alt-title-type="running-head">NKT Cells and Prostate Cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bellone</surname><given-names>Matteo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ceccon</surname><given-names>Monica</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grioni</surname><given-names>Matteo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jachetti</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Calcinotto</surname><given-names>Arianna</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Napolitano</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Freschi</surname><given-names>Massimo</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Casorati</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dellabona</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto Scientifico San Raffaele, Milan, Italy</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto Scientifico San Raffaele, Milan, Italy</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Unit&#x000e0; Operativa Anatomia Patologica, Istituto Scientifico San Raffaele, Milan, Italy</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Universit&#x000e0; Vita Salute San Raffaele, Milan, Italy</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Unutmaz</surname><given-names>Derya</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">New York University, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>bellone.matteo@hsr.it</email> (MB); <email>casorati.giulia@hsr.it</email> (GC); <email>paolo.dellabona@hsr.it</email> (PD)</corresp><fn fn-type="con"><p>Conceived and designed the experiments: MB GC. Performed the experiments: MC MG EJ AC AN MF. Analyzed the data: MB MC MG EJ AC AN MF GC PD. Contributed reagents/materials/analysis tools: MF. Wrote the paper: MB GC PD.</p></fn></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>13</day><month>1</month><year>2010</year></pub-date><volume>5</volume><issue>1</issue><elocation-id>e8646</elocation-id><history><date date-type="received"><day>6</day><month>11</month><year>2009</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2009</year></date></history><permissions><copyright-statement>Bellone et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>CD1d-restricted invariant NKT (iNKT) cells are a subset of T lymphocytes endowed with innate effector functions that aid in the establishment of adaptive T and B cell immune responses. iNKT cells have been shown to play a spontaneous protective role against experimental tumors. Yet, the interplay between iNKT and tumor-specific T cells in cancer immune surveillance/editing has never been addressed. The transgenic adenocarcinoma of the mouse prostate (TRAMP) is a realistic model of spontaneous oncogenesis, in which the tumor-specific cytotoxic T cell (CTL) response undergoes full tolerance upon disease progression.</p></sec><sec><title>Principal Findings</title><p>We report here that lack of iNKT cells in TRAMP mice resulted in the appearance of more precocious and aggressive tumors that significantly reduced animal survival. TRAMP mice bearing or lacking iNKT cells responded similarly to a tumor-specific vaccination and developed tolerance to a tumor-associated antigen at comparable rate.</p></sec><sec><title>Conclusions</title><p>Hence, our data argue for a critical role of iNKT cells in the immune surveillance of carcinoma that is independent of tumor-specific CTL.</p></sec></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Several lines of evidence in pre-clinical and clinical studies support the notion that tumor cell growth is under the active control of the immune system <xref ref-type="bibr" rid="pone.0008646-Dunn1">&#x0005b;1&#x0005d;</xref>. Cancer immune surveillance is the result of concerted actions between innate and adaptive immune responses <xref ref-type="bibr" rid="pone.0008646-Smyth1">&#x0005b;2&#x0005d;</xref>. T cell responses specific for tumor-associated antigens (TAA) presented by MHC molecules on cancer cells play a central role in cancer immune surveillance, and can be increased by different immunotherapy strategies in attempts to cure cancer <xref ref-type="bibr" rid="pone.0008646-Dougan1">&#x0005b;3&#x0005d;</xref>.</p><p>iNKT cells are a subset of conserved T lymphocytes that bridge innate and adaptive immunity <xref ref-type="bibr" rid="pone.0008646-Bendelac1">&#x0005b;4&#x0005d;</xref>. They are characterized by the expression of the homologous invariant (i)V&#x003b1;14-J&#x003b1;18 and V&#x003b1;24-J&#x003b1;18 TCR chains in mice and humans, respectively <xref ref-type="bibr" rid="pone.0008646-Lantz1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Dellabona1">&#x0005b;6&#x0005d;</xref>. The iV&#x003b1; chains pair with a set of variable TCR&#x003b2; chains exhibiting a very restricted V&#x003b2; gene usage: V&#x003b2;8.2, 7 and 2 in mice and V&#x003b2;11 in humans <xref ref-type="bibr" rid="pone.0008646-Bendelac1">&#x0005b;4&#x0005d;</xref>. This semi-invariant TCR recognizes endogenous or exogenous lipid antigens (Ag) presented by the MHC-class I like molecule CD1d <xref ref-type="bibr" rid="pone.0008646-Brigl1">&#x0005b;7&#x0005d;</xref>.</p><p>Unlike MHC-restricted T cells, iNKT cells exhibit an effector-memory phenotype independently of foreign Ag encounter, acquired in the thymus following a distinct developmental pathway <xref ref-type="bibr" rid="pone.0008646-Godfrey1">&#x0005b;8&#x0005d;</xref>. Injection into mice of the CD1d-restricted glycosphingolipid Ag &#x003b1;GalactosylCeramide (&#x003b1;GalCer) potently activates iNKT cells, triggering within hours copious production of a wide range of Th1 and Th2 cytokines <xref ref-type="bibr" rid="pone.0008646-Kronenberg1">&#x0005b;9&#x0005d;</xref>. These cytokines, in turn, activate effector cells of both innate and adaptive immune responses <xref ref-type="bibr" rid="pone.0008646-Kronenberg1">&#x0005b;9&#x0005d;</xref>. iNKT cell interaction with CD1d-expressing immature dendritic cells (DC) results in the licensing of antigen presenting functions, which facilitates priming of CD4<sup>&#x0002b;</sup> and CD8<sup>&#x0002b;</sup> T cell and B cell responses specific for concomitant protein Ag <xref ref-type="bibr" rid="pone.0008646-Fujii1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Tonti1">&#x0005b;11&#x0005d;</xref>. Furthermore, cytokine production by iNKT cells can be triggered independently of TCR engagement, for instance by the action of inflammatory cytokines such as IL-12 and IL-18 <xref ref-type="bibr" rid="pone.0008646-Nagarajan1">&#x0005b;12&#x0005d;</xref>.</p><p>Because of these peculiar innate-like effector characteristics, iNKT cells are regarded as potent adjuvant involved in the early activation of the immune response and in cancer immune surveillance <xref ref-type="bibr" rid="pone.0008646-Cerundolo1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Terabe1">&#x0005b;14&#x0005d;</xref>. Consistent with this function, circulating iNKT cell number have been found reduced in human solid tumors, while IFN-&#x003b3; production and number of iNKT cells appear to correlate with a more favorable prognosis in multiple myeloma, colorectal cancer, head and neck cancer and prostate cancer (PC) <xref ref-type="bibr" rid="pone.0008646-Tahir1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Dhodapkar1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Tachibana1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Molling1">&#x0005b;18&#x0005d;</xref>.</p><p>iNKT cell activation by &#x003b1;GalCer <italic>in vivo</italic> results in the subsequent activation of NK and T cells, leading to the growth control of both transplantable tumors and spontaneous mammary carcinoma <xref ref-type="bibr" rid="pone.0008646-Taniguchi1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Swann1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Hayakawa1">&#x0005b;21&#x0005d;</xref>.</p><p>iNKT cells display also a spontaneous anti-tumor function, which occurs independently of &#x003b1;GalCer administration, possibly induced by the recognition of endogenous lipid antigens. Mice selectively deficient in iNKT cells (J&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice) are in fact significantly more susceptible to chemically induced carcinogenesis <xref ref-type="bibr" rid="pone.0008646-Crowe1">&#x0005b;22&#x0005d;</xref>. In this model, adoptive cell transfer experiments established that the protection from methylcholanthrene (MCA)-induced fibrosarcoma is mediated by IFN-&#x003b3;-producing hepatic CD4<sup>&#x02212;</sup> iNKT cells <xref ref-type="bibr" rid="pone.0008646-Crowe2">&#x0005b;23&#x0005d;</xref>. Furthermore, iNKT cells spontaneously suppress the growth of osteosarcoma and hematopoietic tumors caused in mice by the loss of the tumor suppressor p53 <xref ref-type="bibr" rid="pone.0008646-Swann2">&#x0005b;24&#x0005d;</xref>. Because of the lack of a traceable tumor Ag-specific T cell response in both MCA-induced tumor models and in p53<sup>&#x0002b;/&#x02212;</sup> mice, and development of different and unpredictable tumor types in the latter, it is difficult to correlate the presence or lack of iNKT with tumor-specific a CTL response and its involvement in cancer immune surveillance.</p><p>Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice express the SV40 large T antigen (Tag) in the prostate epithelium under the control of the rat probasin regulatory element. Sexual hormones influence the expression of the transgene <xref ref-type="bibr" rid="pone.0008646-Greenberg1">&#x0005b;25&#x0005d;</xref>; hence, male mice remain healthy until puberty. In the following weeks, TRAMP mice over-express Tag and invariably develop spontaneous mouse prostate intraepithelial neoplasia (mPIN), which progress to adenocarcinoma and seminal vesicles, lymph node (LN) and visceral metastases, resembling human PC <xref ref-type="bibr" rid="pone.0008646-Shappel1">&#x0005b;26&#x0005d;</xref>. In TRAMP mice, the immune response against the surrogate tissue-specific TAA Tag is characterized by thymic deletion of high avidity CTL <xref ref-type="bibr" rid="pone.0008646-Zheng1">&#x0005b;27&#x0005d;</xref>. As a consequence, vaccination with Tag-pulsed DC in young healthy TRAMP mice elicits low avidity CTL specific for the immunodominant sequence Tag<sub>404&#x02013;411</sub> (Tag-IV) <xref ref-type="bibr" rid="pone.0008646-Mylin1">&#x0005b;28&#x0005d;</xref>. In parallel with PC development and progression, these CTL undergo a profound state of peripheral tolerance <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti1">&#x0005b;29&#x0005d;</xref> that cannot be rescued by DC vaccination <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti1">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti2">&#x0005b;30&#x0005d;</xref>. A similar phenomenon has been reported in TRAMP mice for other surrogate <xref ref-type="bibr" rid="pone.0008646-Drake1">&#x0005b;31&#x0005d;</xref> and natural tumor associated antigens <xref ref-type="bibr" rid="pone.0008646-Savage1">&#x0005b;32&#x0005d;</xref>, and recapitulates the tolerant status found in patients with advanced PC disease <xref ref-type="bibr" rid="pone.0008646-Miller1">&#x0005b;33&#x0005d;</xref>.</p><p>Given the data on anti-tumor roles of NKT cells in transplantable and carcinogen tumor models together with the clinical relevance of the TRAMP model, we investigated whether iNKT cells control the growth of spontaneous PC, and whether this phenomenon depends on the interplay between iNKT and tumor-specific T cells.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and Methods</title><sec id="s2a"><title>Mice, Tumor Cell Lines and Reagents</title><p>Heterozygous TRAMP mice on a C57BL/6 background were obtained from Dr. A Vitiello (The R.W. Johnson Pharmaceutical Research Institute, San Diego, CA), originated from the founder male 8247 <xref ref-type="bibr" rid="pone.0008646-Greenberg1">&#x0005b;25&#x0005d;</xref>, and were bred by crossing heterozygous TRAMP females with wild type (WT) C57BL/6 males. B6.129-Tcra-Jtm1tg mice J&#x003b1;18-deficient (J&#x003b1;18<sup>&#x02212;/&#x02212;</sup>) were obtained from Dr. M. Taniguchi (RIKEN, Yokohama, Japan) and backcrossed 12 times to C57BL/6. TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice were generated at San Raffaele by crossing TRAMP and C57BL/6 J&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice. Animals were typed for Tag expression by PCR-based screening assay, as described in (<ext-link ext-link-type="uri" xlink:href="http://www.jax.org">www.jax.org</ext-link>). All mice were housed and bred in a specific pathogen free animal facility. All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee at San Raffaele Scientific Institute. Animals were monitored twice a week for weight and tumor growth, and euthanized when signs of bulky prostate tumor and/or distress were evident. RMA is a H-2<sup>b</sup> Rauscher virus-induced thymoma <xref ref-type="bibr" rid="pone.0008646-Ljunggren1">&#x0005b;34&#x0005d;</xref>. B6/K-0 is a kidney cell line, expressing Tag <xref ref-type="bibr" rid="pone.0008646-Tanaka1">&#x0005b;35&#x0005d;</xref>. TRAMP-C1 is a PC cell line originated from a TRAMP mouse <xref ref-type="bibr" rid="pone.0008646-Foster1">&#x0005b;36&#x0005d;</xref>. Unless specified, all chemical reagents were from Sigma-Aldrich, and mAb were from BD PharMingen (San Diego, CA).</p></sec><sec id="s2b"><title>DC Preparation and Immunization Protocols</title><p>DC were prepared and characterized as previously described <xref ref-type="bibr" rid="pone.0008646-Camporeale1">&#x0005b;37&#x0005d;</xref>. DC were pulsed with 2 &#x000b5;M Tag-IV or 1 &#x000b5;M tyrosinase related protein 2 peptide<sub>181&#x02013;200</sub> (TRP-2; Research Genetics, Huntsville, AL) for 1 h at 37&#x000b0;C, washed, and suspended at 1&#x000d7;10<sup>6</sup>/ml in PBS. Five&#x000d7;10<sup>5</sup> DC were injected i.d. into mice. When requested, &#x003b1;GalCer (100 ng/ml) was added to the DC cultures 3 h before cell recovery. Magnetic-bead (Miltenyi Biotec, Bologna, Italy) enriched CD8<sup>&#x0002b;</sup> splenocytes <xref ref-type="bibr" rid="pone.0008646-Iezzi1">&#x0005b;38&#x0005d;</xref> from mice euthanized one week after DC vaccination were stained with PE-labeled K<sup>b</sup>/Tag-IV or K<sup>b</sup>/OVA (SIINFEKL) pentamers (ProImmune, Oxford, UK), CD8, CD44, and dump (B220, CD11c, CD19, CD4) mAbs and analyzed by flow cytometry <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti1">&#x0005b;29&#x0005d;</xref>. For functional analysis of iNKT cells, &#x003b1;GalCer (2 &#x000b5;g/mouse; Alexis, Lausen, Switzerland) was administered i.v. Blood samples were collected from the tail vein 2, 6 and 24 hours later, and the serum content of IL-4 and IFN-&#x003b3; was determined by standard ELISA (BD Pharmingen, San Diego, CA). Animals were euthanized 72 hours after &#x003b1;GalCer treatment, and the number of iNKT cells in their spleen and liver was determined by staining with &#x003b1;GalCer-mCD1d tetramers (provided by the NIH Tetramer Facility) and anti-TCR&#x003b2; mAbs and flow cytometry analysis <xref ref-type="bibr" rid="pone.0008646-Fedeli1">&#x0005b;39&#x0005d;</xref>.</p></sec><sec id="s2c"><title>In Vitro Cytotoxicity Assay</title><p>Splenocytes were re-stimulated <italic>in vitro</italic> in the presence of 1 &#x000b5;M Tag IV or TRP-2 peptide. Day-5-blasts were tested for cytolytic activity in a standard 4 h <sup>51</sup>Cr release assay <xref ref-type="bibr" rid="pone.0008646-Camporeale1">&#x0005b;37&#x0005d;</xref>. <sup>51</sup>Cr release of target cells alone was always &#x0003c;25&#x00025; of maximal <sup>51</sup>Cr release (target cells in 0.25 M SDS).</p></sec><sec id="s2d"><title>Histology and Immunohistochemistry</title><p>The urogenital apparatus (UGA) was excised, weighted, fixed in 4&#x00025; formalin for 6 h, then embedded and included in paraffin wax. H&#x00026;E and Tag staining of 5-mm thick sections were performed as previously described <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti2">&#x0005b;30&#x0005d;</xref>. Macroscopic and microscopic specimens were evaluated by a pathologist in a blind fashion. Histology sections were scored as previously described <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti2">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Bertilaccio1">&#x0005b;40&#x0005d;</xref> with partial modifications: 0, healthy tissue; &#x0003c;1, scattered (&#x0003c;20&#x00025;) Tag<sup>&#x0002b;</sup> cells with mild increase of nucleus to cytoplasm ratio; 1, &#x02265;20&#x00025; Tag<sup>&#x0002b;</sup> cells with increasing nucleus to cytoplasm ratio, nuclear hyperchromasia, stratification and micro-papillary projections; 2, presence of all the features described in 1 and cribriform structures with mild enlargement of acini; 3, presence of all the features described in 2 and either proliferation of the epithelial and stromal cells of the seminal vesicles or mild proliferation of smooth muscle stromal cells of prostatic acini with acinar enlargement; 4, presence of all the features described in 3 and marked proliferation of smooth muscle stromal cells with penetration of malignant Tag<sup>&#x0002b;</sup> cells through the basement membrane of mPIN-involved glands into the surrounding stroma; 5, well differentiated adenocarcinoma; and 6, presence of metastasis and/or neuroendocrine tumors.</p></sec><sec id="s2e"><title>Statistical Analysis</title><p>Statistical analyses were performed using the Student <italic>t</italic>-test, the Log-Rank and the Mann-Whitney tests. Comparison of survival curves was considered statistically significant for p&#x0003c;0.05.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Survival of TRAMP Mice Lacking iNKT Cells Is Reduced</title><p>To investigate the role of iNKT cells in immune surveillance against a spontaneous solid cancer, we generated male TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice, and compared their survival with a cohort of TRAMP mice. Animals were euthanized when signs of bulky prostate tumor and/or distress were manifest. Anatomy and histology of the UGA confirmed the presence of aggressive prostate tumors in all animals (i.e., disease score &#x02265;4; data not shown). As reported in <xref ref-type="fig" rid="pone-0008646-g001">Fig. 1</xref>, TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice exhibited a reduced disease-free survival, and all animals in this cohort were euthanized before week 38. At this time, approximately 60&#x00025; of the TRAMP animals were still alive and apparently tumor free. Comparison of survival curves of the two cohorts of mice revealed a highly significant prolonged survival for TRAMP mice (p&#x0003c;0.0001). Hence, the lack of iNKT cells appears to greatly affect tumorigenesis in this model.</p><fig id="pone-0008646-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008646.g001</object-id><label>Figure 1</label><caption><title>Survival of TRAMP mice lacking iNKT cells is reduced.</title><p>Kaplan-Maier plot reporting the survival curves of groups of male TRAMP (black squares; n&#x0200a;&#x0003d;&#x0200a;21) and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice (black circles; n&#x0200a;&#x0003d;&#x0200a;21). Animals were examined twice a week and euthanized when signs of bulky prostate tumor and/or distress were manifest. At necropsy, the anatomy and histology of the UGA was analyzed as indicated in the <xref ref-type="sec" rid="s2">Material and Methods</xref> section. Animals were attributed a disease score&#x02265;4. Statistical comparison (Log-Rank test) between the survival curves: p&#x0003c;0.0001.</p></caption><graphic xlink:href="pone.0008646.g001"/></fig></sec><sec id="s3b"><title>Tumor Onset Is Accelerated in TRAMP Mice Lacking iNKT Cells</title><p>To better define the time of appearance and aggressiveness of prostate tumors in TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice, cohorts of TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice were sacrificed at different weeks after birth and full autopsy was performed. Animals with bulky and round-shaped prostate masses, which were histologically confirmed to be neuroendocrine prostate tumors, were excluded from the study because appearance of these lesions is stochastic in the TRAMP model <xref ref-type="bibr" rid="pone.0008646-Chiaverotti1">&#x0005b;41&#x0005d;</xref>. Macroscopically, the UGA of TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice appeared larger than that of age-matched WT and even TRAMP males, with seminal vesicles particularly engorged already at 17&#x02013;18 weeks of age (data not shown). Indeed, the UGA weight, an accepted parameter to measure disease progression in this model, of TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> males was higher than that of age-matched WT mice at weeks 17&#x02013;24, and the difference further increased during the following weeks (<xref ref-type="fig" rid="pone-0008646-g002">Fig. 2A</xref>; p&#x0003c;0.0001). Furthermore, a highly statistically significant difference in UGA weight between TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> and WT or TRAMP mice was present already at 12&#x02013;16 weeks (p&#x0003c;0.0001), time at which there was no difference in UGA weight between TRAMP and WT males (<xref ref-type="fig" rid="pone-0008646-g002">Fig. 2A</xref>).</p><fig id="pone-0008646-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008646.g002</object-id><label>Figure 2</label><caption><title>Tumor onset is accelerated in TRAMP mice lacking iNKT cells.</title><p>Age- and sex-matched male TRAMP (white bars; n&#x0200a;&#x0003d;&#x0200a;97), TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> (black bars; n&#x0200a;&#x0003d;&#x0200a;51) and WT mice (gray bars; n&#x0200a;&#x0003d;&#x0200a;97) were killed at the indicated week after birth and the anatomy and histology of the UGA was analyzed as indicated in the <xref ref-type="sec" rid="s2">Material and Methods</xref> section. Animals affected by neuroendocrine tumors were excluded. A, UGA weight (g), expressed as average&#x000b1;SEM, of TRAMP, TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> and WT mice killed at weeks 6&#x02013;8 (n&#x0200a;&#x0003d;&#x0200a;5, 8 and 19, respectively), 12&#x02013;16 (n&#x0200a;&#x0003d;&#x0200a;16, 17 and 26), 17&#x02013;24 (n&#x0200a;&#x0003d;&#x0200a;30, 15 and 26) and 25&#x02013;28 (n&#x0200a;&#x0003d;&#x0200a;46, 11 and 26), respectively. B, ratio of the weight of UGA and body weight subtracted of the UGA in the groups of animals reported above. C, Disease score, expressed as average&#x000b1;SEM, of the groups of animals reported above. Statistical analysis of collected data was performed using the Student's <italic>t</italic>-test (A and B) and the Mann-Whitney test (C); &#x0002a;&#x0002a;&#x0002a;p&#x0003c;0.001, &#x0002a;&#x0002a;0.001&#x0003c;p&#x0003c;0.05, &#x0002a;0.01&#x0003c;p&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0008646.g002"/></fig><p>Difference in UGA weight was likely due to more advanced/aggressive tumors and not to a generalized increase in body weight of TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice. Indeed, when the ratio of the weight of UGA and body weight subtracted of the UGA was calculated for all groups of animals reported above (<xref ref-type="fig" rid="pone-0008646-g002">Fig. 2A</xref>), differences were all confirmed (<xref ref-type="fig" rid="pone-0008646-g002">Fig. 2B</xref>).</p><p>Prostate tissues were also investigated microscopically. No difference in disease score was present in TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice at 6&#x02013;8 weeks of age, and most of the prostates at H&#x00026;E staining showed scattered foci of cells with nuclear elongation, altered nucleus-to-cytoplasm ratio and micro-papillary projections, sometimes accompanied by cribriform structures and mild enlargement of acini (data not shown). Expression of Tag in 6&#x02013;8 weeks old TRAMP mice and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice had a dim and patchy distribution overlapping pathologic foci (data not shown), with, as expected <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti2">&#x0005b;30&#x0005d;</xref>, a disease score&#x0003c;2 (<xref ref-type="fig" rid="pone-0008646-g002">Fig. 2C</xref>). In the following weeks, lesions in TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice appeared more aggressive than that of age-matched TRAMP animals, and the disease score was significantly higher in TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> than in TRAMP animals at all weeks tested (<xref ref-type="fig" rid="pone-0008646-g002">Fig. 2C</xref>).</p><p>Interestingly, invasive adenocarcinoma (disease score 5) was found in 4 out of 13 (31&#x00025;) TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice and in zero out of 8 18&#x02013;19 week old TRAMP mice. In the TRAMP colony indeed, the earliest invasive adenocarcinoma was found at week 23. When cohorts of mice were sacrificed at week 25&#x02013;28, adenocarcinoma was found in 7 out of 11 (64&#x00025;) TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice versus 7 out of 46 (15&#x00025;) TRAMP mice.</p><p>Hence, spontaneous PC development and progression, as reported for tumors induced by MCA <xref ref-type="bibr" rid="pone.0008646-Crowe1">&#x0005b;22&#x0005d;</xref> or p53 loss <xref ref-type="bibr" rid="pone.0008646-Swann2">&#x0005b;24&#x0005d;</xref>, is more aggressive in TRAMP mice lacking iNKT cells.</p></sec><sec id="s3c"><title>Similar Behavior of Tag-Specific CTL Responses in TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> Mice</title><p>We next sought to investigate whether the iNKT cell-dependent anti-tumor functions could be related to the induction and maintenance of a spontaneous TAA-specific CTL response. The low frequency of tumor-specific CTL in TRAMP mice precluded the direct <italic>ex vivo</italic> comparison of frequency, phenotype and functions in TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti2">&#x0005b;30&#x0005d;</xref>. However, the detection <italic>ex vivo</italic> of tumor-specific CTL responses can be achieved following <italic>in vivo</italic> expansion, obtained upon immunization of TRAMP mice with specific TAA. By immunizing TRAMP mice with DC pulsed with the TAA Tag, we were in fact able to detect a specific CTL response. Furthermore, we previously showed that PC growth is accompanied by the progressive induction of a Tag-specific CTL tolerance that reaches a full state at around 11 weeks of age <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti1">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti2">&#x0005b;30&#x0005d;</xref>.</p><p>To determine whether the precocious and more aggressive PC found in TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> was due to the establishment of Tag-specific CTL tolerance at an earlier stage than in TRAMP mice, TRAMP, TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> and WT mice were immunized once i.d. with Tag-IV pulsed DC at week 6&#x02013;8, when tumor-specific CTL are still functional, and sacrificed one week later. <italic>Ex vivo</italic> flow-cytometry analysis showed a comparable frequency of CD8<sup>&#x0002b;</sup>CD44<sup>&#x0002b;</sup>K<sup>b</sup>/TagIV<sup>&#x0002b;</sup> cells in the spleen of vaccinated TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice (0.9&#x000b1;0.14 and 1.31&#x000b1;0.5&#x00025;, respectively), therefore indicating a similar <italic>in vivo</italic> expansion of Tag-specific T cells in TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice.</p><p>Upon in vitro Ag-specific restimulation, splenocytes from TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> demonstrated a comparable, consistent and specific cytolytic activity against Tag-IV-pulsed RMA cells (<xref ref-type="fig" rid="pone-0008646-g003">Fig. 3A and B</xref>, respectively) that was, as expected <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti2">&#x0005b;30&#x0005d;</xref>, lower than the one found in WT vaccinated mice (<xref ref-type="fig" rid="pone-0008646-g003">Fig. 3C</xref>). CTL blasts efficiently killed also Tag<sup>&#x0002b;</sup> B6/K-0 targets (<xref ref-type="fig" rid="pone-0008646-g003">Fig. 3</xref>), therefore demonstrating that these CTL were able to recognize the endogenously processed and presented SV40 epitope. When cohorts of TRAMP, TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> and WT males were immunized after week 10, at which point, tumor-specific CTL tolerance is full-blown <xref ref-type="bibr" rid="pone.0008646-DeglInnocenti2">&#x0005b;30&#x0005d;</xref>, a Tag-specific immune response was detected only in splenocytes from vaccinated WT animals (<xref ref-type="fig" rid="pone-0008646-g003">Fig. 3</xref>, panels D, E and F, respectively), suggesting that tolerance of Tag-specific CTL proceeded at comparable rates in TRAMP mice bearing or lacking iNKT cells.</p><fig id="pone-0008646-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008646.g003</object-id><label>Figure 3</label><caption><title>The immune response against Tag is comparable in TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice.</title><p>Tag-IV-pulsed DC were injected once i.d. into 6- (panels A&#x02013;C) and 16-week (D&#x02013;F) old male TRAMP (A and D), TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> (B and E) and WT age- and sex-matched littermates (C and F). After 7 days, animals were killed and their splenocytes were stimulated <italic>in vitro</italic> with irradiated B6/K-0 cells, and tested 5 days later for cytotoxic activity (measured as <sup>51</sup>Cr release); un-pulsed (black squares) or Tag-IV-pulsed (black diamonds) RMA and B6/K-0 (black circles) cells were used as targets. Data correspond to one out of at least three independent experiments, which gave similar results.</p></caption><graphic xlink:href="pone.0008646.g003"/></fig><p>To investigate whether lack of immune response against Tag in aged TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice reflected a generalized immune suppression or was specific for the TAA, cohorts of TRAMP, TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> and WT mice were immunized with DC pulsed with the unrelated and K<sup>b</sup>-restricted melanoma antigen TRP-2. As reported in <xref ref-type="fig" rid="pone-0008646-g004">Fig. 4</xref>, all groups of mice generated a comparable TRP-2-specific CTL response, therefore confirming that tolerance in TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice is restricted to the PC-associated antigen.</p><fig id="pone-0008646-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008646.g004</object-id><label>Figure 4</label><caption><title>Tolerance in tumor-bearing mice is specific for the PC-related Ag Tag.</title><p>TRP-2-pulsed DC were injected once i.d. into 16-week old male TRAMP (left panel), TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> (middle panel) and WT age- and sex-matched littermates (right panel). After 7 days, animals were killed and their splenocytes were stimulated <italic>in vitro</italic> with the TRP-2 peptide, and tested 5 days later for cytotoxic activity (measured as <sup>51</sup>Cr release); un-pulsed (black diamonds) or TRP-2-pulsed (black triangles) RMA cells were used as targets. Each panel is representative of at least two independent experiments.</p></caption><graphic xlink:href="pone.0008646.g004"/></fig><p>Since it has been reported that immunization of mice with the iNKT cell strong agonist antigen &#x003b1;GalCer enhances the T cell response specific for a concomitantly administered antigen, mainly via the NKT cell-mediated licensing of DC function <xref ref-type="bibr" rid="pone.0008646-Fujii1">&#x0005b;10&#x0005d;</xref>, we investigated whether the presence of &#x003b1;GalCer on DC could break Tag-specific CTL tolerance in TRAMP mice. As a preliminary experiment, we compared the functional activity of iNKT cells both in TRAMP and WT C57BL/6 male mice by determining the systemic release of IL-4 and IFN&#x003b3; after injection of &#x003b1;GalCer i.v. As expected, IL-4 and IFN&#x003b3; concentration in the serum peaked at 2 and 6 hours after &#x003b1;GalCer injection (<xref ref-type="fig" rid="pone-0008646-g005">Fig. 5</xref>), with no statistically significant differences between TRAMP and WT C57BL/6 mice. Furthermore, both frequency and absolute number of splenic and hepatic iNKT cells, determined by &#x003b1;GalCer-mCD1d tetramer staining, were also comparable between the two strain of mice (data not shown). We then immunized fifteen week-old TRAMP mice with DC pulsed either with Tag-IV and &#x003b1;GalCer or with Tag-IV alone. One week later, the presence of Tag-specific CTL in the immunized mice was determined by <italic>in vitro</italic> restimulation of spleen cells with the TAA. A Tag-specific CTL response, however, could not be found in either group of vaccinated mice (data not shown).</p><fig id="pone-0008646-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008646.g005</object-id><label>Figure 5</label><caption><title>&#x003b1;Gal-Cer-mediated release of iNKT-associated cytokines.</title><p>&#x003b1;GalCer (2 &#x000b5;g/mouse) was administered i.v. to TRAMP (white circles) and WT (black circles) littermates, and blood samples were collected from the tail vein 2, 6 and 24 hours later, and the serum content of IL-4 and IFN-&#x003b3; was determined by standard ELISA. Values are reported as concentration of the cytokine (pg/ml) in the sera of each animal (3&#x02013;4/experimental group) analyzed at the indicated time points. Reported data are representative of at least two independent experiments.</p></caption><graphic xlink:href="pone.0008646.g005"/></fig><p>Taken together, these data suggest that Tag-specific peripheral CTL tolerance, induced by PC development and progression, is not influenced by iNKT cells, and that iNKT cells exert an as yet undefined role in PC immune surveillance in TRAMP mice.</p></sec></sec><sec id="s4"><title>Discussion</title><p>This study demonstrates that iNKT cells play a relevant role in the immune surveillance of spontaneous prostate adenocarcinoma in TRAMP mice, extending substantially the findings that these cells suppress the onset of spontaneous sarcomas and hematopoietic malignanices <xref ref-type="bibr" rid="pone.0008646-Swann2">&#x0005b;24&#x0005d;</xref>. The observation that the lack of iNKT cells correlates with a more aggressive disease in TRAMP mice is consistent with the findings showing that the progression of different types of human cancers, including PC, is accompanied by a significant decrease in iNKT cell number <xref ref-type="bibr" rid="pone.0008646-Tahir1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Dhodapkar1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Tachibana1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Molling1">&#x0005b;18&#x0005d;</xref>. Thus, iNKT cells appear to play an active role both in mice and in humans in controlling different forms of cancer, ranging from hematological malignancies to sarcoma and carcinoma, arguing for an unconstrained capacity of these cells to survey transformed cells in multiple organs and tissues, through as yet unrecognized mechanisms. Furthermore, our results underscore the relevance of the TRAMP model for deciphering the mechanisms by which the immune system controls solid tumor outgrowth.</p><p>iNKT cells display a powerful helper activity for adaptive T as well as B cell responses, exerted mainly via enhancing antigen presenting functions in DC <xref ref-type="bibr" rid="pone.0008646-Fujii1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Tonti1">&#x0005b;11&#x0005d;</xref>, which result in facilitated priming of peptide-specific CD4<sup>&#x0002b;</sup> and CD8<sup>&#x0002b;</sup> T cell responses. Furthermore, iNKT cells reduce the immunosuppressive activity of influenza A virus&#x02013;induced Gr1<sup>&#x0002b;</sup>CD11b<sup>&#x0002b;</sup>/CD15<sup>&#x0002b;</sup>CD11b<sup>&#x0002b;</sup> myeloid precursors in mice and humans, respectively, by promoting their maturation into functional DC <xref ref-type="bibr" rid="pone.0008646-DeSanto1">&#x0005b;42&#x0005d;</xref>. Given that Gr1<sup>&#x0002b;</sup>CD11b<sup>&#x0002b;</sup> myeloid precursors share phenotypic and functional characteristics with myeloid-derived suppressor cells (MDSC) <xref ref-type="bibr" rid="pone.0008646-Sica1">&#x0005b;43&#x0005d;</xref>, iNKT cells might exert their anti-tumor effector functions via modulation of MDSC activity, resulting in a reduced suppression of tumor-specific T cell responses <xref ref-type="bibr" rid="pone.0008646-Renukaradhya1">&#x0005b;44&#x0005d;</xref>. Such mechanisms could enhance tumor-specific T cell response as well. However, such Gr1<sup>&#x0002b;</sup>CD11b<sup>&#x0002b;</sup> cells appear defective and may actually suppress iNKT cells in tumor-bearing animals <xref ref-type="bibr" rid="pone.0008646-Yanagisawa1">&#x0005b;45&#x0005d;</xref></p><p>We did not find evidence that supports a correlation between the presence of iNKT cells in TRAMP mice and either the efficiency of the Tag-specific CTL response or a decreased induction of tolerance toward Tag. Indeed, Tag-specific tolerance appeared at similar rates in TRAMP and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice, and could not be broken by immunization with DC pulsed with Tag-IV plus &#x003b1;GalCer. Moreover, we have found that the frequency and function of MDSC as well as CD4<sup>&#x0002b;</sup>CD25<sup>&#x0002b;</sup>Foxp3<sup>&#x0002b;</sup> regulatory T cells <xref ref-type="bibr" rid="pone.0008646-Sakaguchi1">&#x0005b;46&#x0005d;</xref> are similar in TRAMP &#x0005b;<xref ref-type="bibr" rid="pone.0008646-DeglInnocenti1">&#x0005b;29&#x0005d;</xref> and Capuano G. et al., manuscript in preparation&#x0005d; and TRAMPJ&#x003b1;18<sup>&#x02212;/&#x02212;</sup> mice (data not shown), suggesting that a direct cross-talk between iNKT cells and MDSC or regulatory T cells is not a relevant mechanism in TRAMP mice. Altogether, these data provide indirect evidence that iNKT cells are not involved in controlling the induction of CTL tolerance in TRAMP mice and, consequently, the anti-tumor effector T cell response.</p><p>Studies performed <italic>in vitro</italic> have shown that human iNKT can be directly cytotoxic against CD1d<sup>&#x0002b;</sup> tumor cell targets. The expression of CD1d has been detected on some types of primary human leukemia blasts <xref ref-type="bibr" rid="pone.0008646-Metelitsa1">&#x0005b;47&#x0005d;</xref> and on glioma cells <xref ref-type="bibr" rid="pone.0008646-Dhodapkar2">&#x0005b;48&#x0005d;</xref>. However, the expression of CD1d on mouse tumor cells seems more frequent <xref ref-type="bibr" rid="pone.0008646-Fiedler1">&#x0005b;49&#x0005d;</xref> and our preliminary data suggest that mouse primary PC cells from TRAMP mice express CD1d (data not shown). Nevertheless, it should be taken into consideration that in the absence of strong exogenous ligands such as &#x003b1;GalCer, iNKT exhibit little cytotoxic activity against CD1d<sup>&#x0002b;</sup> mouse and human tumor cells <xref ref-type="bibr" rid="pone.0008646-Metelitsa1">&#x0005b;47&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008646-Kawano1">&#x0005b;50&#x0005d;</xref>. Therefore, whether iNKT cells can directly kill tumor cells <italic>in vivo</italic> remains to be established. Interestingly, in this context, human iNKT cells can kill macrophages that are supposed to infiltrate human neuroblastoma in a CD1d-dependent manner <xref ref-type="bibr" rid="pone.0008646-Song1">&#x0005b;51&#x0005d;</xref>, providing a mechanistic link between neuroblastoma infiltration by iNKT cells and an improved prognosis <xref ref-type="bibr" rid="pone.0008646-Song1">&#x0005b;51&#x0005d;</xref>. We can therefore speculate that mouse iNKT cells may control PC growth in TRAMP mice by limiting the number or altering the function of tumor associated macrophages (TAM), which play an important role in supporting neoangiogenesis and tumor growth <xref ref-type="bibr" rid="pone.0008646-Allavena1">&#x0005b;52&#x0005d;</xref> via IFN-&#x003b3; production.</p><p>The definition of the mechanism by which iNKT cells control mouse PC growth warrants future investigation.</p></sec></body><back><ack><p>We thank M.P. Protti (Istituto Scientifico San Raffaele, Milan, Italy) and M.A. Exley (Beth Israel-Deaconess Medical Center and Harvard Medical School, Boston, MA) for helpful discussions and critical comments on the manuscript.</p></ack><ref-list><title>Reference</title><ref id="pone.0008646-Dunn1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><year>2004</year><article-title>The three Es of cancer immunoediting.</article-title><source>Annu Rev Immunol</source><volume>22</volume><fpage>329</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">15032581</pub-id></mixed-citation></ref><ref id="pone.0008646-Smyth1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><year>2006</year><article-title>Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.</article-title><source>Adv Immunol</source><volume>90</volume><fpage>1</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">16730260</pub-id></mixed-citation></ref><ref id="pone.0008646-Dougan1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougan</surname><given-names>M</given-names></name><name><surname>Dranoff</surname><given-names>G</given-names></name></person-group><year>2009</year><article-title>Immune therapy for cancer.</article-title><source>Annu Rev Immunol</source><volume>27</volume><fpage>83</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">19007331</pub-id></mixed-citation></ref><ref id="pone.0008646-Bendelac1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendelac</surname><given-names>A</given-names></name><name><surname>Savage</surname><given-names>PB</given-names></name><name><surname>Teyton</surname><given-names>L</given-names></name></person-group><year>2007</year><article-title>The biology of NKT cells.</article-title><source>Annu Rev Immunol</source><volume>25</volume><fpage>297</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">17150027</pub-id></mixed-citation></ref><ref id="pone.0008646-Lantz1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lantz</surname><given-names>O</given-names></name><name><surname>Bendelac</surname><given-names>A</given-names></name></person-group><year>1994</year><article-title>An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4&#x0002b; and CD4&#x02013;8&#x02212; T cells in mice and humans.</article-title><source>J Exp Med</source><volume>180</volume><fpage>1097</fpage><lpage>1106</lpage><pub-id pub-id-type="pmid">7520467</pub-id></mixed-citation></ref><ref id="pone.0008646-Dellabona1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellabona</surname><given-names>P</given-names></name><name><surname>Padovan</surname><given-names>E</given-names></name><name><surname>Casorati</surname><given-names>G</given-names></name><name><surname>Brockhaus</surname><given-names>M</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year>1994</year><article-title>An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4&#x02013;8&#x02212; T cells.</article-title><source>J Exp Med</source><volume>180</volume><fpage>1171</fpage><lpage>1176</lpage><pub-id pub-id-type="pmid">8064234</pub-id></mixed-citation></ref><ref id="pone.0008646-Brigl1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brigl</surname><given-names>M</given-names></name><name><surname>Brenner</surname><given-names>MB</given-names></name></person-group><year>2004</year><article-title>CD1: antigen presentation and T cell function.</article-title><source>Annu Rev Immunol</source><volume>22</volume><fpage>817</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">15032598</pub-id></mixed-citation></ref><ref id="pone.0008646-Godfrey1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godfrey</surname><given-names>DI</given-names></name><name><surname>Berzins</surname><given-names>SP</given-names></name></person-group><year>2007</year><article-title>Control points in NKT-cell development.</article-title><source>Nat Rev Immunol</source><volume>7</volume><fpage>505</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">17589542</pub-id></mixed-citation></ref><ref id="pone.0008646-Kronenberg1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kronenberg</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>Toward an understanding of NKT cell biology: progress and paradoxes.</article-title><source>Annu Rev Immunol</source><volume>23</volume><fpage>877</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">15771592</pub-id></mixed-citation></ref><ref id="pone.0008646-Fujii1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Bonifaz</surname><given-names>L</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name></person-group><year>2003</year><article-title>Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.</article-title><source>J Exp Med</source><volume>198</volume><fpage>267</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">12874260</pub-id></mixed-citation></ref><ref id="pone.0008646-Tonti1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonti</surname><given-names>E</given-names></name><name><surname>Galli</surname><given-names>G</given-names></name><name><surname>Malzone</surname><given-names>C</given-names></name><name><surname>Abrignani</surname><given-names>S</given-names></name><name><surname>Casorati</surname><given-names>G</given-names></name><etal/></person-group><year>2009</year><article-title>NKT-cell help to B lymphocytes can occur independently of cognate interaction.</article-title><source>Blood</source><volume>113</volume><fpage>370</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">18832653</pub-id></mixed-citation></ref><ref id="pone.0008646-Nagarajan1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagarajan</surname><given-names>NA</given-names></name><name><surname>Kronenberg</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>Invariant NKT cells amplify the innate immune response to lipopolysaccharide.</article-title><source>J Immunol</source><volume>178</volume><fpage>2706</fpage><lpage>2713</lpage><pub-id pub-id-type="pmid">17312112</pub-id></mixed-citation></ref><ref id="pone.0008646-Cerundolo1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerundolo</surname><given-names>V</given-names></name><name><surname>Silk</surname><given-names>JD</given-names></name><name><surname>Masri</surname><given-names>SH</given-names></name><name><surname>Salio</surname><given-names>M</given-names></name></person-group><year>2009</year><article-title>Harnessing invariant NKT cells in vaccination strategies.</article-title><source>Nat Rev Immunol</source><volume>9</volume><fpage>28</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">19079136</pub-id></mixed-citation></ref><ref id="pone.0008646-Terabe1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terabe</surname><given-names>M</given-names></name><name><surname>Berzofsky</surname><given-names>JA</given-names></name></person-group><year>2007</year><article-title>NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis.</article-title><source>Trends Immunol</source><volume>28</volume><fpage>491</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">17964217</pub-id></mixed-citation></ref><ref id="pone.0008646-Tahir1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahir</surname><given-names>SM</given-names></name><name><surname>Cheng</surname><given-names>O</given-names></name><name><surname>Shaulov</surname><given-names>A</given-names></name><name><surname>Koezuka</surname><given-names>Y</given-names></name><name><surname>Bubley</surname><given-names>GJ</given-names></name><etal/></person-group><year>2001</year><article-title>Loss of IFN-gamma production by invariant NK T cells in advanced cancer.</article-title><source>J Immunol</source><volume>167</volume><fpage>4046</fpage><lpage>4050</lpage><pub-id pub-id-type="pmid">11564825</pub-id></mixed-citation></ref><ref id="pone.0008646-Dhodapkar1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhodapkar</surname><given-names>MV</given-names></name><name><surname>Geller</surname><given-names>MD</given-names></name><name><surname>Chang</surname><given-names>DH</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.</article-title><source>J Exp Med</source><volume>197</volume><fpage>1667</fpage><lpage>1676</lpage><pub-id pub-id-type="pmid">12796469</pub-id></mixed-citation></ref><ref id="pone.0008646-Tachibana1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tachibana</surname><given-names>T</given-names></name><name><surname>Onodera</surname><given-names>H</given-names></name><name><surname>Tsuruyama</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>A</given-names></name><name><surname>Nagayama</surname><given-names>S</given-names></name><etal/></person-group><year>2005</year><article-title>Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas.</article-title><source>Clin Cancer Res</source><volume>11</volume><fpage>7322</fpage><lpage>7327</lpage><pub-id pub-id-type="pmid">16243803</pub-id></mixed-citation></ref><ref id="pone.0008646-Molling1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molling</surname><given-names>JW</given-names></name><name><surname>Langius</surname><given-names>JA</given-names></name><name><surname>Langendijk</surname><given-names>JA</given-names></name><name><surname>Leemans</surname><given-names>CR</given-names></name><name><surname>Bontkes</surname><given-names>HJ</given-names></name><etal/></person-group><year>2007</year><article-title>Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma.</article-title><source>J Clin Oncol</source><volume>25</volume><fpage>862</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">17327607</pub-id></mixed-citation></ref><ref id="pone.0008646-Taniguchi1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name><name><surname>Kojo</surname><given-names>S</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Wakao</surname><given-names>H</given-names></name></person-group><year>2003</year><article-title>The regulatory role of Valpha14 NKT cells in innate and acquired immune response.</article-title><source>Annu Rev Immunol</source><volume>21</volume><fpage>483</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">12543936</pub-id></mixed-citation></ref><ref id="pone.0008646-Swann1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swann</surname><given-names>J</given-names></name><name><surname>Crowe</surname><given-names>NY</given-names></name><name><surname>Hayakawa</surname><given-names>Y</given-names></name><name><surname>Godfrey</surname><given-names>DI</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><year>2004</year><article-title>Regulation of antitumour immunity by CD1d-restricted NKT cells.</article-title><source>Immunol Cell Biol</source><volume>82</volume><fpage>323</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">15186264</pub-id></mixed-citation></ref><ref id="pone.0008646-Hayakawa1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayakawa</surname><given-names>Y</given-names></name><name><surname>Rovero</surname><given-names>S</given-names></name><name><surname>Forni</surname><given-names>G</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><year>2003</year><article-title>Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.</article-title><source>Proc Natl Acad Sci U S A</source><volume>100</volume><fpage>9464</fpage><lpage>9469</lpage><pub-id pub-id-type="pmid">12867593</pub-id></mixed-citation></ref><ref id="pone.0008646-Crowe1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowe</surname><given-names>NY</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Godfrey</surname><given-names>DI</given-names></name></person-group><year>2002</year><article-title>A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas.</article-title><source>J Exp Med</source><volume>196</volume><fpage>119</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">12093876</pub-id></mixed-citation></ref><ref id="pone.0008646-Crowe2"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowe</surname><given-names>NY</given-names></name><name><surname>Coquet</surname><given-names>JM</given-names></name><name><surname>Berzins</surname><given-names>SP</given-names></name><name><surname>Kyparissoudis</surname><given-names>K</given-names></name><name><surname>Keating</surname><given-names>R</given-names></name><etal/></person-group><year>2005</year><article-title>Differential antitumor immunity mediated by NKT cell subsets in vivo.</article-title><source>J Exp Med</source><volume>202</volume><fpage>1279</fpage><lpage>1288</lpage><pub-id pub-id-type="pmid">16275765</pub-id></mixed-citation></ref><ref id="pone.0008646-Swann2"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swann</surname><given-names>JB</given-names></name><name><surname>Uldrich</surname><given-names>AP</given-names></name><name><surname>van Dommelen</surname><given-names>S</given-names></name><name><surname>Sharkey</surname><given-names>J</given-names></name><name><surname>Murray</surname><given-names>WK</given-names></name><etal/></person-group><year>2009</year><article-title>Type I NKT cells suppress tumors in mice caused by p53 loss.</article-title><source>Blood Feb 20 &#x0005b;Epub ahead of print&#x0005d;</source></mixed-citation></ref><ref id="pone.0008646-Greenberg1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>NM</given-names></name><name><surname>DeMayo</surname><given-names>F</given-names></name><name><surname>Finegold</surname><given-names>MJ</given-names></name><name><surname>Medina</surname><given-names>D</given-names></name><name><surname>Tilley</surname><given-names>WD</given-names></name><etal/></person-group><year>1995</year><article-title>Prostate cancer in a transgenic mouse.</article-title><source>Proc Natl Acad Sci U S A</source><volume>92</volume><fpage>3439</fpage><lpage>3443</lpage><pub-id pub-id-type="pmid">7724580</pub-id></mixed-citation></ref><ref id="pone.0008646-Shappel1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shappel</surname><given-names>SB</given-names></name><name><surname>Thomas</surname><given-names>GV</given-names></name><name><surname>Roberts</surname><given-names>RL</given-names></name><name><surname>Herbert</surname><given-names>R</given-names></name><name><surname>Ittmann</surname><given-names>MM</given-names></name><etal/></person-group><year>2004</year><article-title>Prostate pathology of genetically engineered mice: definitions and Classification. The consensus report from the Bar Harbor meeting of the mouse models of Human Cancer Consortium Prostate Pathology Commitee.</article-title><source>Cancer Res</source><volume>64</volume><fpage>2270</fpage><lpage>2305</lpage><pub-id pub-id-type="pmid">15026373</pub-id></mixed-citation></ref><ref id="pone.0008646-Zheng1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>JX</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Geiger</surname><given-names>TL</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><year>2002</year><article-title>Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors.</article-title><source>J Immunol</source><volume>169</volume><fpage>4761</fpage><lpage>4769</lpage><pub-id pub-id-type="pmid">12391185</pub-id></mixed-citation></ref><ref id="pone.0008646-Mylin1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mylin</surname><given-names>LM</given-names></name><name><surname>Schell</surname><given-names>TD</given-names></name><name><surname>Roberts</surname><given-names>D</given-names></name><name><surname>Epler</surname><given-names>M</given-names></name><name><surname>Boesteanu</surname><given-names>A</given-names></name><etal/></person-group><year>2000</year><article-title>Quantitation of CD8(&#x0002b;) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes.</article-title><source>J Virol</source><volume>74</volume><fpage>6922</fpage><lpage>6934</lpage><pub-id pub-id-type="pmid">10888631</pub-id></mixed-citation></ref><ref id="pone.0008646-DeglInnocenti1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degl'Innocenti</surname><given-names>E</given-names></name><name><surname>Grioni</surname><given-names>M</given-names></name><name><surname>Capuano</surname><given-names>G</given-names></name><name><surname>Jachetti</surname><given-names>E</given-names></name><name><surname>Freschi</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><article-title>Peripheral T-cell tolerance associated with prostate cancer is independent from CD4&#x0002b;CD25&#x0002b; regulatory T cells.</article-title><source>Cancer Res</source><volume>68</volume><fpage>292</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">18172322</pub-id></mixed-citation></ref><ref id="pone.0008646-DeglInnocenti2"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degl'Innocenti</surname><given-names>E</given-names></name><name><surname>Grioni</surname><given-names>M</given-names></name><name><surname>Boni</surname><given-names>A</given-names></name><name><surname>Camporeale</surname><given-names>A</given-names></name><name><surname>Bertilaccio</surname><given-names>MT</given-names></name><etal/></person-group><year>2005</year><article-title>Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.</article-title><source>Eur J Immunol</source><volume>35</volume><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">15597325</pub-id></mixed-citation></ref><ref id="pone.0008646-Drake1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drake</surname><given-names>CG</given-names></name><name><surname>Doody</surname><given-names>AD</given-names></name><name><surname>Mihalyo</surname><given-names>MA</given-names></name><name><surname>Huang</surname><given-names>CT</given-names></name><name><surname>Kelleher</surname><given-names>E</given-names></name><etal/></person-group><year>2005</year><article-title>Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.</article-title><source>Cancer Cell</source><volume>7</volume><fpage>239</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">15766662</pub-id></mixed-citation></ref><ref id="pone.0008646-Savage1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>PA</given-names></name><name><surname>Vosseller</surname><given-names>K</given-names></name><name><surname>Kang</surname><given-names>C</given-names></name><name><surname>Larimore</surname><given-names>K</given-names></name><name><surname>Riedel</surname><given-names>E</given-names></name><etal/></person-group><year>2008</year><article-title>Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8&#x0002b; T lymphocytes.</article-title><source>Science</source><volume>319</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">18187659</pub-id></mixed-citation></ref><ref id="pone.0008646-Miller1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>AM</given-names></name><name><surname>Pisa</surname><given-names>P</given-names></name></person-group><year>2007</year><article-title>Tumor escape mechanisms in prostate cancer.</article-title><source>Cancer Immunol Immunother</source><volume>56</volume><fpage>81</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">16362411</pub-id></mixed-citation></ref><ref id="pone.0008646-Ljunggren1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Karre</surname><given-names>K</given-names></name></person-group><year>1985</year><article-title>Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism.</article-title><source>J Exp Med</source><volume>162</volume><fpage>1745</fpage><lpage>1759</lpage><pub-id pub-id-type="pmid">3877776</pub-id></mixed-citation></ref><ref id="pone.0008646-Tanaka1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Tevethia</surname><given-names>SS</given-names></name></person-group><year>1988</year><article-title>In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones.</article-title><source>J Immunol</source><volume>140</volume><fpage>4348</fpage><lpage>4354</lpage><pub-id pub-id-type="pmid">2453578</pub-id></mixed-citation></ref><ref id="pone.0008646-Foster1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>BA</given-names></name><name><surname>Gingrich</surname><given-names>JR</given-names></name><name><surname>Kwon</surname><given-names>ED</given-names></name><name><surname>Madias</surname><given-names>C</given-names></name><name><surname>Greenberg</surname><given-names>NM</given-names></name></person-group><year>1997</year><article-title>Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.</article-title><source>Cancer Res</source><volume>57</volume><fpage>3325</fpage><lpage>3330</lpage><pub-id pub-id-type="pmid">9269988</pub-id></mixed-citation></ref><ref id="pone.0008646-Camporeale1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camporeale</surname><given-names>A</given-names></name><name><surname>Boni</surname><given-names>A</given-names></name><name><surname>Iezzi</surname><given-names>G</given-names></name><name><surname>Degl'Innocenti</surname><given-names>E</given-names></name><name><surname>Grioni</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes.</article-title><source>Cancer Res</source><volume>63</volume><fpage>3688</fpage><lpage>3694</lpage><pub-id pub-id-type="pmid">12839960</pub-id></mixed-citation></ref><ref id="pone.0008646-Iezzi1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iezzi</surname><given-names>G</given-names></name><name><surname>Boni</surname><given-names>A</given-names></name><name><surname>Degl'Innocenti</surname><given-names>E</given-names></name><name><surname>Grioni</surname><given-names>M</given-names></name><name><surname>Bertilaccio</surname><given-names>MT</given-names></name><etal/></person-group><year>2006</year><article-title>Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses.</article-title><source>J Immunol</source><volume>177</volume><fpage>2131</fpage><lpage>2137</lpage><pub-id pub-id-type="pmid">16887972</pub-id></mixed-citation></ref><ref id="pone.0008646-Fedeli1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedeli</surname><given-names>M</given-names></name><name><surname>Napolitano</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>MP</given-names></name><name><surname>Marcais</surname><given-names>A</given-names></name><name><surname>de Lalla</surname><given-names>C</given-names></name><etal/></person-group><year>2009</year><article-title>Dicer-dependent microRNA pathway controls invariant NKT cell development.</article-title><source>J Immunol</source><volume>183</volume><fpage>2506</fpage><lpage>2512</lpage><pub-id pub-id-type="pmid">19625646</pub-id></mixed-citation></ref><ref id="pone.0008646-Bertilaccio1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertilaccio</surname><given-names>S</given-names></name><name><surname>Grioni</surname><given-names>M</given-names></name><name><surname>Sutherland</surname><given-names>BW</given-names></name><name><surname>Degl'Innocenti</surname><given-names>E</given-names></name><name><surname>Freschi</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><article-title>Vasculature-Targeted Tumor Necrosis Factor-Alpha Increases the Therapeutic Index of Doxorubicin Against Prostate Cancer.</article-title><source>The Prostate Apr 24 &#x0005b;Epub ahead of print&#x0005d;</source></mixed-citation></ref><ref id="pone.0008646-Chiaverotti1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiaverotti</surname><given-names>T</given-names></name><name><surname>Couto</surname><given-names>SS</given-names></name><name><surname>Donjacour</surname><given-names>A</given-names></name><name><surname>Mao</surname><given-names>JH</given-names></name><name><surname>Nagase</surname><given-names>H</given-names></name><etal/></person-group><year>2008</year><article-title>Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.</article-title><source>Am J Pathol</source><volume>172</volume><fpage>236</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">18156212</pub-id></mixed-citation></ref><ref id="pone.0008646-DeSanto1"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Santo</surname><given-names>C</given-names></name><name><surname>Salio</surname><given-names>M</given-names></name><name><surname>Masri</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>LY</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><etal/></person-group><year>2008</year><article-title>Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans.</article-title><source>J Clin Invest</source><volume>118</volume><fpage>4036</fpage><lpage>4048</lpage><pub-id pub-id-type="pmid">19033672</pub-id></mixed-citation></ref><ref id="pone.0008646-Sica1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Bronte</surname><given-names>V</given-names></name></person-group><year>2007</year><article-title>Altered macrophage differentiation and immune dysfunction in tumor development.</article-title><source>J Clin Invest</source><volume>117</volume><fpage>1155</fpage><lpage>1166</lpage><pub-id pub-id-type="pmid">17476345</pub-id></mixed-citation></ref><ref id="pone.0008646-Renukaradhya1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renukaradhya</surname><given-names>GJ</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Vieira</surname><given-names>M</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Gervay-Hague</surname><given-names>J</given-names></name><etal/></person-group><year>2008</year><article-title>Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.</article-title><source>Blood</source><volume>111</volume><fpage>5637</fpage><lpage>5645</lpage><pub-id pub-id-type="pmid">18417738</pub-id></mixed-citation></ref><ref id="pone.0008646-Yanagisawa1"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>K</given-names></name><name><surname>Exley</surname><given-names>MA</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Ohkochi</surname><given-names>N</given-names></name><name><surname>Taniguchi</surname><given-names>M</given-names></name><etal/></person-group><year>2006</year><article-title>Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b&#x0002b; Gr-1&#x0002b; cells producing nitric oxide.</article-title><source>Cancer Res</source><volume>66</volume><fpage>11441</fpage><lpage>11446</lpage><pub-id pub-id-type="pmid">17145891</pub-id></mixed-citation></ref><ref id="pone.0008646-Sakaguchi1"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><year>2005</year><article-title>Naturally arising Foxp3-expressing CD25&#x0002b;CD4&#x0002b; regulatory T cells in immunological tolerance to self and non-self.</article-title><source>Nat Immunol</source><volume>6</volume><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">15785760</pub-id></mixed-citation></ref><ref id="pone.0008646-Metelitsa1"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metelitsa</surname><given-names>LS</given-names></name><name><surname>Weinberg</surname><given-names>KI</given-names></name><name><surname>Emanuel</surname><given-names>PD</given-names></name><name><surname>Seeger</surname><given-names>RC</given-names></name></person-group><year>2003</year><article-title>Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.</article-title><source>Leukemia</source><volume>17</volume><fpage>1068</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">12764370</pub-id></mixed-citation></ref><ref id="pone.0008646-Dhodapkar2"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhodapkar</surname><given-names>KM</given-names></name><name><surname>Cirignano</surname><given-names>B</given-names></name><name><surname>Chamian</surname><given-names>F</given-names></name><name><surname>Zagzag</surname><given-names>D</given-names></name><name><surname>Miller</surname><given-names>DC</given-names></name><etal/></person-group><year>2004</year><article-title>Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion.</article-title><source>Int J Cancer</source><volume>109</volume><fpage>893</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">15027123</pub-id></mixed-citation></ref><ref id="pone.0008646-Fiedler1"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiedler</surname><given-names>T</given-names></name><name><surname>Walter</surname><given-names>W</given-names></name><name><surname>Reichert</surname><given-names>TE</given-names></name><name><surname>Maeurer</surname><given-names>MJ</given-names></name></person-group><year>2002</year><article-title>Regulation of CD1d expression by murine tumor cells: escape from immunosurveillance or alternate target molecules?</article-title><source>Int J Cancer</source><volume>98</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">11920590</pub-id></mixed-citation></ref><ref id="pone.0008646-Kawano1"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawano</surname><given-names>T</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Koezuka</surname><given-names>Y</given-names></name><name><surname>Toura</surname><given-names>I</given-names></name><name><surname>Kaneko</surname><given-names>Y</given-names></name><etal/></person-group><year>1998</year><article-title>Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.</article-title><source>Proc Natl Acad Sci U S A</source><volume>95</volume><fpage>5690</fpage><lpage>5693</lpage><pub-id pub-id-type="pmid">9576945</pub-id></mixed-citation></ref><ref id="pone.0008646-Song1"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Asgharzadeh</surname><given-names>S</given-names></name><name><surname>Salo</surname><given-names>J</given-names></name><name><surname>Engell</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>HW</given-names></name><etal/></person-group><year>2009</year><article-title>Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.</article-title><source>J Clin Invest</source><volume>119</volume><fpage>1524</fpage><lpage>1536</lpage><pub-id pub-id-type="pmid">19411762</pub-id></mixed-citation></ref><ref id="pone.0008646-Allavena1"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year>2008</year><article-title>The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.</article-title><source>Immunol Rev</source><volume>222</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">18364000</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>Associazione Italiana per la Ricerca sul Cancro: <ext-link ext-link-type="uri" xlink:href="http://www.airc.it">www.airc.it</ext-link> Ministero del lavoro, della salute e delle politiche sociali: <ext-link ext-link-type="uri" xlink:href="http://www.ministerosalute.it/">www.ministerosalute.it/</ext-link> Fondazione CARIPLO: <ext-link ext-link-type="uri" xlink:href="http://www.fondazionecariplo.it">www.fondazionecariplo.it</ext-link> Association for International Cancer Research: <ext-link ext-link-type="uri" xlink:href="http://www.aicr.org.uk">www.aicr.org.uk</ext-link> The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>